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Objective: To investigate the long-term disease course of patients with recently deteriorated systemic
sclerosis (SSC)-interstitial lung disease (ILD) undergoing continuous immunosuppressive treatment with
cyclophosphamide (CYC) as induction therapy.
Methods: A total of 45 consecutive SSc patients were treated with weekly pulses of 500 mg of CYC up to
10-g cumulative dose followed by azathioprine (AZA) in those experiencing improvement (410%
increase) or stabilization of both forced vital capacity and diffusion lung capacity for carbon dioxide
and by micophenolic acid (MMF) in those experiencing deterioration (410% decrease of either
parameter). The follow-up ranged from 6 to 62 months post-CYC regimen (median ¼ 36 months).
Results: Overall, 39 patients completed the CYC regimen. Of them, 24 (61.5%) experienced improvement
or stabilization of lung function parameters and received AZA; the remaining 15 received MMF. During
follow-up, lung function parameters improved in 3 (12.5%), remained stable in 18 (75%), and worsened in
3 (12.5%) AZA-treated patients, whereas they worsened in 8 (67%) and remained stable in 4 (33%) MMF-
treated patients. The incidence of improvement or stabilization was signiﬁcantly higher in AZA-treated
than in MMF-treated patients (p ¼ 0.001). The time to the decline of lung function was signiﬁcantly
shorter in CYC non-responders, and CYC unresponsiveness was predictive of lung function worsening
over time in a multivariate analysis (HR ¼ 9.14; 95% CI: 2.28–36.64; p ¼ 0.0018).
Conclusion: Our study supports the use of low-dose pulse CYC as induction therapy of recently
deteriorated SSc-ILD. Moreover, it suggests that AZA should be administered to CYC-responsive patients
but does not show any deﬁnite effect of MMF in unresponsive patients.
& 2014 Published by Elsevier Inc.Introduction
Systemic sclerosis (SSc) is an autoimmune systemic disease
characterized by skin ﬁbrosis, vascular abnormalities, and internal
organ involvement and associated with a shortened survival [1].
Interstitial lung disease (ILD) is one of the leading causes of death
in SSc patients and is still a therapeutic challenge [1–3]. Since the
pivotal article by Silver et al. [3], a number of studies have
investigated the efﬁcacy of cyclophosphamide (CYC) in the treat-
ment of ILD in SSc patients, including 2 randomized controlled
studies, namely the Scleroderma Lung Study (SLS) [4] and thealentini).Fibrosing Alveolitis in Scleroderma Trial (FAST) [5], and many
observational studies [3,6–22].
Based on the results of these studies, the European Scleroderma
Trial and Research (EUSTAR) group recommended that patients
with SSc-ILD be treated with CYC [23]. Subsequently, however, 2
meta-analyses did not ﬁnd any clinically signiﬁcant difference with
respect to placebo in the SLS and FAST controlled trials and found
just a freezing effect in observational studies [24,25]. Moreover,
the SLS trial pointed out that the small differences observed
between the treatment group and the placebo gradually vanished
from 6 months after CYC interruption, which suggests a role for a
maintenance immunosuppressive treatment [26]. In that context,
Berezne et al. [15] retrospectively investigated the course of SSc-
ILD in 27 SSc patients and reported that 14 of the 19 patients
responding to a 6-monthly course of pulse CYC and treated with
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stable respiratory function at 2-year follow-up. We previously
reported that the protocol devised by researchers at St. Thomas's
Hospital in London [27], namely, CYC at weekly low-dose pulses
(500 mg) followed by oral AZA, was effective and safe in patients
with early diffuse SSc-ILD [28,29].
We undertook the present 6-year, prospective, observational
study to assess the effectiveness of low-dose pulse CYC up to 10 g,
followed, according to a treat-to-target strategy, by AZA in res-
ponder patients and by micophenolic acid (MMF) in non-
responders.Materials and methods
Patients admitted from November 1, 2007 to October 31, 2012
to the Rheumatology Unit of the Second University of Naples and
satisfying the 1980 American College of Rheumatology criteria for
the classiﬁcation of SSc [30] and/or the LeRoy and Medsger [31]
criteria for early SSc, who had experienced a recent worsening of
lung function, were enrolled in the study after giving their written
informed consent.
All patients were assessed with the EUSTAR Minimal Essential
Data Set [32] and were divided into 2 subsets (diffuse and limited
cutaneous; dc- and lc-SSc) according to the subsetting scheme of
LeRoy et al. [33]. Autoantibody proﬁle was investigated as pre-
viously described [34]. Disease duration was calculated from the
onset of the ﬁrst non-Raynaud's phenomenon sign/symptom.
To be included in the study, patients had to show a signiﬁcant
deterioration of lung function during the previous 6 months, i.e.,
a decrease of forced vital capacity (FVC) and/or diffusion lung
capacity for carbon dioxide (DLCO) greater than 10% of the
respective predicted values with respect to previous values, in
absence of a chronic obstructive pulmonary disease. In patients
experiencing an isolated reduction of DLCO, a predeﬁned workup
designed to rule out pulmonary hypertension and to ascribe the
ﬁnding to ILD was made. This consisted an evaluation of systolic
pulmonary arterial pressure (sPAP) at echocardiography, serum
pro-brain natriuretic peptide [35], and high-resolution computed
tomography (HRCT) of the lungs. A bronchoalveolar lavage (BAL)
analysis was proposed in patients without changes on HRCT
consistent with SSc-ILD to conﬁrm the presence of alveolitis and
rule out an infection. Pulmonary function tests including FVC,
forced expiratory volume in 1 min (FEV1), and DLCO, expressed as
percentages of predicted values based on age, sex, and height and
corrected for hemoglobin level, were performed according to
techniques accepted by the American Thoracic Society (ATS)
[36,37]. The percentage predicted DLCO reported value was the
average of at least 2 acceptable tests meeting the reproducibility
requirements of ATS [36]. At chest HRCT, images were obtained
with 1-mm collimation and 10-mm intervals at maximal end-
inspiratory phase with the patient in a supine position using a high
spatial frequency algorithm. If needed, prone scans were added to
distinguish gravity-related changes from structural abnormalities.
The presence of bilateral ground-glass and/or ﬁbrotic abnormal-
ities involving at least both bases was considered consistent with
SSc-ILD. The extent of the disease was deﬁned according to Goh
et al. [38]. A bronchoalveolar lavage analysis was performed
according to a standardized procedure. Alveolitis was diagnosed
when the percentage of neutrophils in the BAL ﬂuid was Z3% or
when the percentage of eosinophils was Z2%, or both [39].
Induction CYC therapy
Patients were treated with weekly pulses of 500 mg of CYC up
to a cumulative dose of 10 g (20 pulses). All patients received oralcorticosteroids (7.5–10 mg/day prednisone equivalent) and stand-
ard therapy with proton pump inhibitors, calcium channel block-
ers, antiplatelet agents, and vitamin D supplementation. No other
immunosuppressive drug was allowed.
To prevent CYC-induced cystitis, hydration and Mesna of
100 mg (before each CYC pulse and 4 and 8 h after) were
administered. To monitor toxic effects, weekly blood count, liver
function tests (alanine aminotransferase and aspartate amino-
transferase), and urinalysis were performed. If the white blood
cells level was below 3000 per mm3 or neutrophils below 1500 per
mm3 and/or if liver enzymes level increased above 2.0 times the
upper normal range value, the subsequent CYC pulse was delayed
until normalization of these parameters.
All patients received oral trimethoprim–sulfamethoxazole
(160–800 mg) 3 times per week to prevent Pneumocystis jirovecii
infection.Sequential therapy with AZA or MMF
At the end of the low-dose CYC pulses, patients were reeval-
uated at 6-month intervals by history, clinical examination, and
pulmonary function tests. At completion of the 20 planned CYC
pulses, patients experiencing a signiﬁcant functional improvement
(i.e., an FVC increase 410% of predicted value with respect to
entry values) were deﬁned “improved,” those with an FVC change
between 10% and þ10% were deﬁned “stable,” and those with an
FVC decline 410% were deﬁned “worsened.” In addition, we also
considered “worsened” patients with a stable FVC and a DLCO
decrease 410% vs basal values. Patients with improved or stable
disease were deﬁned “CYC responders.” Those with a stable FVC
who developed a decrease of DLCO 410% and those whose FVC
had worsened were deﬁned “CYC non-responders.” CYC respond-
ers were treated with oral azathioprine (AZA) (2 mg/kg/day),
whereas CYC non-responders were treated with oral micophenolic
acid (MMF) (2 g/day). To monitor toxic effects of these drugs, blood
count and liver function tests (alanine aminotransferase and
aspartate aminotransferase) were performed before starting the
therapy, after 2 and 4 weeks, and then every month.
Patients were monitored for a median of 48 months (range:
18–72). Those undergoing AZA or MMF treatment and experienc-
ing either an improvement or a stabilization of FVC vs values
recorded upon completion of CYC pulses continued the treatment
up to October 31, 2013; those showing a decrease of FVC and/or
DLCO 410% were considered as treatment failure and censored at
this point for the analysis of the effectiveness and were monitored
only for safety and disease status up to October 31, 2013.
Finally, since DLCO can present a signiﬁcant degree of varia-
bility and it is also inﬂuenced by vascular pulmonary disease, we
performed a post-hoc analysis limited to the 13 patients enrolled
for a decline of FVC associated or not with a decline in DLCO, and
we used the FVC as response parameter both at the end of CYC
induction therapy and during maintenance immunosuppression
with AZA or MMF. Moreover, we also analyzed the treatment
effectiveness in patients at a higher risk to worsen, i.e., anticen-
tromere (ACA) negative with at least one feature among anti-Scl-
70 positivity, a signiﬁcant FVC worsening, or a diffuse extension of
ﬁbrosis at HRCT, using FVC as the measure to deﬁne the response.
The study was approved by the Ethics Committee of the
Azienda Ospedaliera Seconda Università di Napoli.
Statistical analysis
Continuous variables were analyzed with unpaired Student's
t-test or with the Mann–Whitney test as appropriate. The chi-
square test or Fisher's exact test was applied for categorical
Table 1
Main epidemiologic, clinical, and laboratory features of patients enrolled in the
study
Patients' characteristics
Age (yrs) mean 7 SD 49.86 7 13.33
Females, n (%) 41 (91.1)
Diffuse disease, n (%) 8 (17.7)
Disease duration from ﬁrst non-Raynaud, yrs, mean 7 SD 6.9 7 5.7
Dyspnea, n (%) 18 (40.0)
Body mass index (kg/m2), mean 7 SD 25.8 7 4.7
Modiﬁed Rodnan skin score median (range) 3 (0–27)
FVC %, mean 7 SD 81.46 7 15.94
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analyze differences in lung function changes in different sub-
groups of patients. Logistic regression analysis was used to assess
the correlations between response to CYC and baseline features of
each patient including demographic, clinical and serological fac-
tors, pulmonary function, HRCT scores, and smoking status. Uni-
variate and multivariate Cox regression analyses were performed
to identify the predictors of lung parameters worsening during the
follow-up. p o0.05 was considered statistically signiﬁcant. Stat-
istical analysis was performed using SPSS software, version 12.0.1
(SPSS Inc., Chicago, IL).DLCO%, mean 7 SD 51.48 7 11.95
Antinuclear antibodies, n (%) 45 (100)
Anticentromere antibodies, n (%) 9 (20)
Anti-Scl-70 antibodies, n (%) 27 (60)
Nucleolar pattern, n (%) 1 (2)
HAQ-DI score median (range) 0.25 (0–2.625)
Previous immunosuppressive treatment, n (%) 11 (24.4)
Smoking status
Current smoker, n (%) 12 (26.6)
Ex-smoker, n (%) 6 (13.4)
Never-smoker, n (%) 27 (60)
Yrs, years; SD, standard deviation; n, number; FVC, forced vital capacity; DLCO,
diffusion lung capacity for carbon dioxide; HAQ-DI, health assessment question-
naire-disability index.Results
Baseline features of the patients
From November 1, 2007 to October 31, 2012 45 patients re-
admitted to the Rheumatology Unit of the Second University of
Naples were found to present a decrease of FVC and/or DLCO
410% compared with previous values. All of them were enrolled
in the study after giving a written informed consent. Most were
women (91.1%) with a mean (SD) age and disease duration from
ﬁrst non-Raynaud phenomenon sign/symptom of 49.8 7 13.3
years and 6.9 7 5.7 years, respectively. Among the patients, 8
(17.7%) had dcSSc and 27 (60%) were anti-Scl-70-positive. At
enrollment, mean FVC was 81.4 7 15.9% and mean DLCO was
51.4 7 11.9% in the whole cohort. In detail, the mean percent FVC
was 84.8 7 14.1% in lcSSc and 64.5 7 15.2% in dcSSc patients (p ¼
0.0007); the mean DLCO was 56.6 7 11.5% in lcSSc patients and
41.5713.4% in dcSSc patients (p ¼ 0.002). In each patient, the
presence of chronic obstructive respiratory disease was ruled out.
CYC therapy was administered because of a signiﬁcant decrease of
FVC 7 DLCO in 16 patients (35.5%) and of DLCO in 29 (64.4%). In
detail, considering all the cohort, the FVC mean (SD) percentage
before the signiﬁcant decline was 85.8 7 14.6 (last FVC pre-
treatment was 81.4 7 15.9%), the mean (SD) percentage DLCO was
62.3 7 14.7 (last DLCO pre-treatment was 51.4 7 11.9%). The
median interval between the 2 evaluations was 8 months. As
concerns patients enrolled for a decline of FVC 7 DLCO, the mean
(SD) FVC and DLCO values preceding the signiﬁcant fall were 76.0
7 9.5 (last FVC pre-treatment was 64.7 7 9.4%) and 60.8 7 11
(last DLCO pre-treatment was 47.8 7 13.2%), respectively. Among
patients enrolled for an isolated fall of DLCO, the previous DLCO
value was 65.6 7 11.4% (last DLCO pre-treatment was 53.0 7
11.3%). All the latter patients had normal serum NT-proBNP levels,
16/29 presented HRCT ﬁndings consistent with ILD; the remaining
13 underwent a BAL analysis, which revealed alveolitis and ruled
out infection.
Table 1 lists the main epidemiologic, clinical, and laboratory
features of the patients enrolled. Among the 45 patients, 11 had
been treated with methotrexate for skin disease and/or muscu-
loskeletal involvement. The 20 low-dose pulse CYC regimen was
completed in 39 patients. CYC was discontinued in 4 patients for
safety reasons: 1 because of onset of urticarial lesions (after 10
infusions), 1 because of drug-induced fever (after 7 infusions),
1 because of skin induration prevented access to a peripheral
venous, and the patient declined implant of a central catheter
(after 7 infusions), and 1 because of thrombocytopenia (after 12
infusions). Overall, 2 patients withdrew consent (after 3 and 12
infusions).
Upon completion of CYC pulses, 24/39 (61.5%) patients were
deﬁned “CYC responders.” In detail, FVC improved in 9/39 (23.0%),
and both FVC and DLCO stabilized in 15/39 (38.4%). Among the
9 improved patients, 3 had been enrolled due to a reduction of FVC
and DLCO and 6 due to an isolated decline of DLCO ascribed to ILD,as assessed by lung HRCT in 4 and BAL analysis in 2 patients.
Among the 15 stable patients, 6 had been enrolled because of a
reduction of both FVC and DLCO and 9 because of an isolated DLCO
reduction. Of the 20 (25%) patients with a stable FVC, 5 experienced
a reduction of DLCO 410% (2 had been enrolled because of a
reduction of both FVC and DLCO and 3 because of an isolated
reduction in DLCO). Finally, 10/39 patients (25.6%) were deﬁned
“worse” (4 had been enrolled for a reduction of both FVC and DLCO
and 6 for an isolated reduction of DLCO). There were no signiﬁcant
difference between CYC responders and non-responders in terms
of epidemiologic, clinical, and laboratory features at study entry,
except for the extent of HRCT lung involvement (Table 2). Actually,
a limited HRCT disease extent according to Goh et al. [38] was
found to be associated with CYC response at multiple logistic
regression analyses (OR ¼ 5.25; 95% CI: 1.05–25.78; p ¼ 0.034).
Effectiveness of AZA or MMF
After completion of CYC pulses, patients were monitored for a
median of 36 months (range: 6–62). Duration of follow-up did not
differ between CYC responders (median ¼ 39 months; range:
6–62) and CYC non-responders (median ¼ 47 months; range:
12–60) (p ¼ 0.213). The 24 CYC responders received AZA, whereas
the 12 CYC non-responders, i.e., 7 with a decreased FVC and 5 with
a stable FVC associated with DLCO deterioration 410%, received
MMF. The 3 other non-responders were enrolled in a clinical trial
with imatinib (NCT00573326) and were not considered in this
follow-up analysis.
Among the 24 CYC responders, FVC improved in 3 (12.5%),
remained stable in 18 (75%), and worsened in 3 (12.5%). DLCO
worsened only in 1 patient who had a parallel decline of FVC. Of
the 3 improved patients, 1 had been enrolled because of a
reduction of FVC and DLCO and 2 because of an isolated reduction
of DLCO. Of the 18 stable patients, 5 were enrolled in the study
because of a decline of FVC 7 DLCO and 12 because of an isolated
reduction of DLCO. Of the 12 patients treated with MMF, FVC
worsened in 3 patients (25%); it remained stable in 9 (75%)
patients, among whom, however, 5 had a signiﬁcant decrease of
DLCO. Therefore, a further decline of lung function was detected in
8 of the 12 patients treated with MMF.
Table 2
Baseline main epidemiologic, clinical, and laboratory features of CYC responders compared to CYC non-responders
CYC responders, n ¼ 24 CYC non-responders, n ¼ 15 p
Age (yrs) mean 7 SD 52.5 7 13.5 46.4 7 11.4 0.09
Females, n (%) 22 (91.6) 13 (86.6) 0.630
Diffuse disease, n (%) 2 (8.3) 3 (20.0) 0.354
Disease duration from Raynaud onset (yrs), mean 7 SD 12.8 7 12.1 10.67 7 9.4 0.457
Dyspnea, n % 11 (45.8) 6 (40.0) 0.752
Body mass index (kg/m2), median (range) 25.6 (19.5–37.5) 26.8 (19.9–38.7) 0.09
Modiﬁed Rodnan skin score, median (range) 3 (0–14) 2 (0–27) 0.898
FVC %, mean 7 SD 84.0 7 16.0 77.6 7 15.3 0.109
DLCO%, mean 7 SD 51.8 7 11.1 51.94 7 12.7 0.709
sPAP (mmHg), mean 7 SD 18.8 (15.3) 20.53 (10.8) 0.722
Antinuclear antibodies, n (%) 24 (100) 15 (100) –
Anticentromere antibodies, n (%) 6 (25.0) 1 (6.6) 0.215
Anti-Scl-70 antibodies, n (%) 13 (54.1) 11 (73.3) 0.317
Nucleolar pattern, n (%) 1 (4.1) 0 (0) 1.00
HAQ-DI score, median (range) 0.125 (0–2.625) 0.375 (0–1.875) 0.851
Smoking status
Current smoker, n (%) 6 (25) 3 (20.0) 1.00
Ex-smoker, n (%) 2 (8.3) 3 (20.0) 0.629
Nonsmoker, n (%) 16 (66.6) 9 (60.0) 0.739
HRCT abnormalities
Limited disease by Goh score, n (%) 17 (70.8) 6 (40.0) 0.030
Yrs, years; FVC, forced vital capacity; DLCO, diffusion lung for carbon monoxide; HAQ-DI, health assessment questionnaire-disability index; HRCT, high-resolution computed
tomography.
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series.
The rate of improvement or stabilization was signiﬁcantly
higher in CYC responders treated with AZA than in CYC non-
responders treated with MMF (21/24 vs 4/12; p ¼ 0.001).
Considering completion of CYC pulses as time 0, Kaplan–Meier
curves showed a signiﬁcantly longer time to FVC and/or DLCOEnrol
Completing the induction th
N=39
FVC improved
N=9 (23.1%)
FVC stable 
DLCO stable or improved
N=15 (38.4%)
AZA 
N=24
Stable
N=18 (75.0%)
Worsened
N=3 (12.5%)
*   3 patients were enrolled in a trial
with imatinib (NCT00573326)
Improved
N=3 (12.5%)
Fig. 1. Summary of the disease course in our series. FVC, forced vital capacity; DLCO, diffworsening in lcSSc and CYC responders compared to dcSSc patients
(χ2 ¼ 4.95, p ¼ 0.02) and CYC non-responders (χ2 ¼ 16.02; p ¼
0.023), respectively (Fig. 2). CYC non-responsiveness was the only
feature predictive of lung function worsening over time in multi-
variate analysis (HR ¼ 9.14; 95% CI: 2.28–36.64; p ¼ 0.0018).
The 13 SSc patients enrolled for a decline of FVC associated
or not with a decline in DLCO were mostly females (84.6%),led patients
N=45
Dropped out during the 
induction therapy
N= 6
erapy
FVC stable 
DLCO  worsened>10%
N=5 (12.9%)
Improved
N=0 (0%)
FVC stable
DLCO stable
N=4 (33.3%)
Worsened
N=3 (25.0%)
MMF 
N=12
FVC worsened
N=7+3* (25.6%) 
FVC Freezed
DLCO worsened>10%
N=5 (41.6%)
usion lung capacity for carbon dioxide; AZA, azathioprine; MMF, micophenolic acid.
Fig. 2. Time to worsening FVC and/or DLCO in CYC responders and CYC non-
responders.
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mean disease duration from ﬁrst non-Raynaud onset of 6.9 7
7.2 years. They presented at baseline FVC (% of the predicted
values) values ranging from 49 to 74 (median ¼ 68) and DLCO
values ranging from 28 to 72 (median ¼ 48). Of them, 9 (69.2%)
resulted to be CYC responders (in 3 FVC improved, i.e., increased
410% with respect to basal value, and in 6 it remained stable, i.e.,
declined less than 10% or increased less than 10%) at the end of
induction therapy. This ﬁgure was not statistically different from
that regarded in the 26 patients enrolled for a decline in DLCO
(p ¼ 0.704).
The 16 SSc patients at higher risk of worsening (i.e., ACA-
negative patients with at least one feature among anti-Scl-70
positivity, a signiﬁcant FVC worsening, or a diffuse extension of
ﬁbrosis at HRCT) enrolled were mostly females (81.2%), with a
mean age of 47.1 7 11.3 years and a mean disease duration from
ﬁrst non-Raynaud onset of 6.4 7 6.9 years. Of them, 13 were anti-
Scl-70 positive (6 with a recent signiﬁcant FVC decline, 2 with
extensive ﬁbrosis at HRCT, and 5 with both features). The remain-
ing 3 patients were ANA positive without any autoantibody
speciﬁcity; 2 had been enrolled for a signiﬁcant FVC worsening;
1 presented an extensive ﬁbrosis at HRCT. The patients presented
baseline FVC (% of the predicted values) values ranging from 49 to
78 (median ¼ 68) and DLCO ranging from 28 to 76 (median ¼ 48).
Of them, 11 (68.7%) resulted to be CYC responders (in 3 FVC
improved, i.e., increased 410% with respect to basal value, and in
8 it remained stable, i.e., declined less than 10% or increased less
than 10%) at the end of induction therapy. Among the 11 res-
ponders, 8 received AZA and 3 received MMF for a signiﬁcant
worsening of DLCO. All the CYC non-responders received MMF.
Overall, 3 of 11 CYC responders (all treated with MMF) and 1 of
5 CYC non-responders (p ¼ 1.00) worsened during the follow-up.
However, a median shorter follow-up was recorded in non-
responders (12 months vs 36 months; p ¼ 0.02). This could
explain the lack of difference in response rate in this subanalysis.
Overall, no patient treated with AZA and 4 of 8 patients treated
with MMF (p ¼ 0.07) worsened during follow-up. The median
follow-up was not signiﬁcantly different between the 2 groups
(p ¼ 0.08).Adverse events
Adverse events caused CYC discontinuation in 3 instances: in
1 because of drug-induced fever, in 1 because of thrombocytope-
nia, and in 1 because of the onset of urticarial lesions requiring
hospital admission. Transient adverse events not requiring CYC
discontinuation were nausea in 13 of 45 patients (28.8%), urinary
infections in 6 patients (13.3%), upper respiratory tract infectionsin 4 patients (8.8%), diarrhea in 4 patients (8.8%), myalgias and
muscular cramps in 3 patients (6.6%), and hypertransaminasemia
in 1 patient (2.2%). Transient microhematuria was recorded in
6 patients, but hemorrhagic cystitis was not detected at cysto-
scopy. Patients treated with AZA experienced the following
adverse events: pneumonitis (1 patient), transient hair loss (2
patients), and transient hypertransaminasemia (2 patients). None
of them discontinued the drug. Adverse events resulted in MMF
discontinuation in 2 instances. In 1 patient, the drug was discon-
tinued because of the onset of articular and muscular pain and in
another because of a low platelet count. The latter patient did not
experience lung function deterioration. Transient adverse events
recorded in patients taking MMF were dyspepsia (3 patients),
herpes zoster infection (1 patient), and pneumonitis (1 patient).
One patient who worsened on AZA after 18 months of treat-
ment and dropped out from the effectiveness study died from lung
cancer 2 years after CYC discontinuation. One patient developed
breast cancer 4 months after CYC discontinuation due to poor
venous access after 7 pulses; thus, a causal relationship between
the drug and cancer seems unlikely. Lastly, 1 non-responder to CYC
died from respiratory insufﬁciency 5 years after completing CYC
therapy.Discussion
This is the ﬁrst, long-term observational study on continuous
immunosuppressive treatment in patients with SSc-ILD. We
undertook this prospective, observational study to investigate
the efﬁcacy and safety proﬁle of low-dose pulse CYC up to 10 g
and the long-term disease course of SSc-ILD under continuous
immunosuppressive treatment with either AZA or MMF depend-
ing on the response to the ﬁrst CYC course.
First, we would underline a peculiar characteristic of our series,
which has been reported by others [40], namely, a high percentage
of anti-Scl-70-positive cases. This feature might affect the compar-
ison between our data and those of others but does not affect the
conclusions of the study.
In our study, 29 of the 45 original set of patients had been
enrolled because of a decline of DLCO only, and 5 of the patients
completing the CYC course were deﬁned “non-responders” for the
same reason. DLCO is not considered a validated outcome measure
of SSc-ILD since it can be inﬂuenced by lung vascular disease [41].
However, we excluded such an involvement in our patients and
can thus afﬁrm that DLCO decrease depended on ILD in all cases.
The initial CYC course resulted in an improvement/stabilization
of lung function in 62% of the 39 patients who completed the
regimen. Patients enrolled for an isolated reduction of DLCO had
response rates similar to those enrolled for a reduction of FVC 7
DLCO in terms of both CYC response after 20 pulses (9/13 vs 15/26;
p ¼ 0.728) and number of patients in whom maintenance therapy
led to improvement or stabilization of lung parameters (5/12 vs
6/24; p ¼ 0.445). This response rate is similar to that reported in a
small prospective study of 13 SSc patients treated monthly with
intravenous CYC and methylprednisolone pulses, i.e., stabilization
of lung function at 48 months in 60% of patients [20]. It is also
similar to that reported in the following 2 retrospective studies: by
White et al. [9], in 39 SSc patients with alveolitis diagnosed by BAL
analysis or lung biopsy and treated with oral (35 patients) or pulse
(4 patients) CYC and monitored for 16 months, and by Mittoo et al.
[22], who followed up 38 SSc patients treated with oral CYC for
alveolitis diagnosed by BAL analysis for a median of 4.5 years.
Since DLCO is not considered a primary end point in ILD
treatment studies for both pathophysiological and variability
reasons [42] and an isolated DLCO was shown by Steen et al.
[41] to predict a PAH in 11% of 153 SSc patients, we performed a
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of FVC associated or not with a decline in DLCO. We used the FVC
as response parameter both at the end of CYC induction therapy
and after maintenance immunosuppression with AZA or MMF. We
detected a favorable outcome in a percentage of patients not
different from that included in the study for a decline in DLCO both
at the end of induction (9/13 vs 15/26; p ¼ 0.728) and of
maintenance immunosuppression treatment (5/12 vs 6/24; p ¼
0.445). These results support the validity of the conclusions made
considering the changes detected in the whole series. In that
regard, it is important to underline that 20 of the 73 patients (27%)
admitted to Pittsburgh Unit with an isolated reduction of DLCO
developed a restrictive pattern during the follow-up and, more
importantly, 22% of them already presented pulmonary ﬁbrosis as
detected by chest x-ray at baseline and 43% were found to present
this feature at the end of a 5.4-year follow-up (range: 2.0–13.2)
[41]. Accordingly, we would be inclined to think that our patients
are similar to these Pittsburgh patients.
Since the course of SSc-ILD is variable [24,25], it could be
hypothesized that the results registered in patients who presented
stable values over time refer to a subset of SSc-ILD patients who
were not going to decline. In that regard, we would underline that
FVC freezing has long been used to identify treatment responders
[9,10]. Moreover, obtaining such a result with a less-aggressive
treatment seems worthwhile. CYC treatment in ILD-ACA-positive
patients enrolled for a decline in DLCO could be regarded as a
useless intervention because of the low propensity of such patients
to worsen. In order to avoid this bias, we conducted a further post-
hoc analysis restricted to the 16 SSc patients a at higher risk to
worsen, i.e., ACA-negative patients with at least one feature among
anti-Scl-70 positivity, a signiﬁcant FVC worsening, or a diffuse
extension of ﬁbrosis at HRCT. In these patients also, we registered a
high percentage of response to treatment by using FVC as an
outcome measure. Therefore, whether or not SSc-ILD patients with
a recent isolated decline of DLCO should be treated, the present
study shows that the low-dose CYC pulse regimen also works in
SSC-ILD patients with a high risk of worsening.
Unlike other studies, we enrolled only patients with recent
deterioration of lung function and found that a limited extent of
lung involvement at HRCT according to Goh et al. [38] was
predictive of CYC response. These data mean that the low-dose
pulse CYC regimen used by us shows its greatest effectiveness in
these conditions.
SLS pointed out the need of continuous immunosuppressive
treatment because of the observation that differences between
patients treated with CYC and placebo vanished since 18 months
after CYC introduction. In this context, Berezne et al. [15] treated
27 patients affected by a worsening ILD with 6-monthly CYC pulses
followed by AZA for 18 months. Of the patients who failed to
respond to CYC, 5 were treated with MMF. They reported that the
percentage of patients with stable or improved FVC or total lung
capacity (TLC) after 2 years of follow-up was not signiﬁcantly
different from the one recorded by us after 48 months. Similar to
Berezne et al. [15], we administered AZA to CYC responders but
used MMF in CYC non-responders according to a predeﬁned
strategy. The incidence of improvement during follow-up was
12.5% in AZA patients, whereas no patient on MMF improved.
Lung function stabilized in 75.0% of our patients taking AZA
compared to only 33% of patients treated with MMF. Therefore,
MMF was able to arrest the deterioration of lung function
experienced under CYC in 4 out of 12 (33%) of patients who
completed the CYC course and were found to be unresponsive to it.
Our data support the use of CYC as induction therapy in SSc-
ILD. Nevertheless, CYC cannot be identiﬁed as the gold-standard
induction therapy to be introduced in any SSc-ILD patient. Further
studies are needed to understand which patients should beselected for each drug that is so far shown to be effective in SSc-
ILD, i.e., cyclophosphamide, azathioprine, mycophenolate, and
rituximab [3–22,43–48]. Moreover, the moderate dosage of MMF
used by us in CYC non-responders might have negatively inﬂu-
enced the results obtained with this drug.
Other drugs have been tried as ﬁrst-line treatment in patients
affected by ILD, but the evidence cannot be considered conclusive.
Rituximab, as ﬁrst-line treatment, has been reported to increase
both FVC and DLCO in 8 patients treated after 1 [43] and 2 years of
follow-up [44]. Imatinib has been found to preserve lung function
in 20 patients [45]. MMF has been reported to improve DLCO and
stabilize FVC after 4–6 months of treatment in 6 patients [46], to
improve FVC but not DLCO after 1 year in 11/13 patients [47], and
to stabilize either FVC or DLCO in 17 patients monitored for 1 year
and in 8 patients monitored for 2 years [48]. However, a recent
case–control study did not ﬁnd any difference in lung function
parameter changes between patients treated with MMF and those
treated with CYC and monitored for 2 years [49]. However, a
deterioration of lung HRCT ﬁndings was observed in patients
treated with MMF but not in those treated with CYC [49].
Few studies have evaluated how to manage SSc-ILD patients
after CYC failure. Furuya and Kuwana [50] did not ﬁnd bosentan
effective in 9 patients ineligible or unresponsive to CYC. In a case
series, 7 patients were treated with MMF as maintenance therapy
after CYC, but the authors did not state if patients were CYC
responders or not [51]. Haroon et al. [52] report a patient
unresponsive to CYC in whom treatment with rituximab led to a
clinical improvement.
We found that MMF at 2 g/day had only a “stabilizing” effect in
4/12 patients unresponsive to CYC. Consequently, MMF at that
dosage should not be considered the strategy of choice in patients
unresponsive to CYC. In an observational trial conducted with 15
SSc patients affected by early diffuse disease treated with MMF up
to 3 g/day, Derk et al. [53] observed signiﬁcant improvements in
skin scores, peripheral vascular involvement, and patient-
perceived health status and no worsening in pulmonary function
parameters. Our study does not exclude that MMF at a higher
dosage could be more effective. Nevertheless, the treatment of
SSc-ILD unresponsive to CYC still represents a challenge. The lack
of serial lung HRCTs could be regarded as a limitation of our study.
However, the extent and the type of lung involvement detected by
HRCT are considered a possible secondary outcome measure [42],
and, more importantly, HRCT changes over time do not necessarily
parallel FVC/DLCO changes [49].
Enrolling SSc patients with a recent deterioration of lung
physiology parameters has been considered a tool to conﬁne the
study to patients with active disease. Nevertheless, because of
their long disease duration, our patients could be considered at
low risk to develop end-stage lung disease. However, Khanna et al.
[54] pointed out FVC deterioration over time that was similar in
patients with disease duration from the 1st non-Raynaud's phe-
nomenon 44 years and in those with a disease duration o4
years. Moreover, as pointed out by Medsger et al. [55], even a
difference in FVC or DLCO as small as 10% (i.e., between grade
1 and grade 2 or grade 2 and grade 3 in lung severity scale) can
affect survival. Therefore, we think that the results of our study are
worthwhile, in particular, if the safety of the protocol used by us is
considered. Actually, we used the St. Thomas's Hospital scheme
because it was associated with a lower burden of side effects
compared to long-term oral CYC intake. CYC administered at a
dosage as high as 2 mg/kg/day per os for long periods could cause
such severe side effects as infections, infertility, and cancer [56]. In
point of fact, the burden of adverse events detected by us is
somewhat lower that than reported in previous studies with oral
CYC. In the study by White et al. [9], of the 39 patients with
alveolitis treated with oral CYC, 4 (10.2%) were hospitalized for
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developed alopecia. Tashkin et al. [4] reported that leukopenia
(19 of 79; 24%), neutropenia (7 of 79; 8.8%), and pneumonia (6 of
79 patients; 7.5%) were more frequent in patients treated with CYC
than in a placebo group, and moreover, withdrawals were more
numerous in the treated patients. Moreover, despite the short
follow-up period, 3 malignant cancers were diagnosed. On the
contrary, we had to discontinue CYC for adverse events only in 3
cases. Notably, only 1 serious adverse event was recorded, and the
potential consequences of oral CYC intake such as alopecia,
hemorrhagic cystitis, or cancers did not occur. There was only
1 case of hematologic toxicity (thrombocytopenia). Therefore,
our study supports the use of the low-dose pulse protocol.Conclusion
We found that about 60% of patients who completed the low-
pulse dose regimen, which is associated to a lower burden of side
effects, experienced an improvement or freezing of lung function,
i.e., ﬁgures similar to those recorded with higher CYC doses.
Moreover, we found that AZA further improved or stabilized lung
function in about 90% of them, whereas MMF, at a dosage of 2 g/
day, was just able to freeze lung function in 33% of CYC non-
responders. Therefore, our results support the use of low-dose
pulse CYC, followed by AZA, in CYC responders but do not show
any deﬁnite effect of MMF, at least at that dosage, in CYC non-
responders.Acknowledgments
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